View Older Stories View More Recent Stories

Oct 28, 2025 06:30AM WELIREG plus LENVIMA meets key endpoint in kidney cancer trial
Oct 28, 2025 06:30AM Merck and Eisai Announce WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carc
Oct 27, 2025 06:45AM FDA expands WINREVAIR approval to reduce death and hospitalization risk in PAH
Oct 27, 2025 06:45AM U.S. FDA Approves Updated Indication for WINREVAIR™ (sotatercept-csrk) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension) Based on Phase 3 ZENITH Study
Oct 23, 2025 06:45AM Merck to present phase 3 results for oral PCSK9 inhibitor at AHA meeting
Oct 23, 2025 06:45AM Merck to Present New Data from Its Innovative Cardio-Pulmonary Pipeline and Portfolio at AHA Scientific Sessions 2025
Oct 23, 2025 06:00AM FDA grants priority review for Merck's KEYTRUDA cancer treatments
Oct 23, 2025 06:00AM FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each in Combination with Padcev® (enfortumab vedotin-ejfv), for Certain
Oct 21, 2025 06:45AM Merck presents data on pneumococcal vaccine coverage at IDWeek
Oct 21, 2025 06:45AM Systematic Review of 15 Studies Focused on Epidemiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in U.S. Adults
Oct 20, 2025 08:46AM Merck KEYTRUDA shows long-term survival benefits in lung cancer patients
Oct 20, 2025 08:45AM KEYTRUDA® (pembrolizumab) Demonstrates Long-Term Survival Benefit in Certain Patients With Earlier or Advanced Stages of Non-Small Cell Lung Cancer (NSCLC)
Oct 20, 2025 06:45AM Merck begins construction of $3 billion manufacturing facility in Virginia
Oct 20, 2025 06:45AM Merck Breaks Ground on $3 Billion Center of Excellence for Pharmaceutical Manufacturing in Elkton, Virginia
Oct 19, 2025 08:45AM Daiichi Sankyo and Merck's ovarian cancer drug shows 50.5% response rate
Oct 19, 2025 08:45AM Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-O
Oct 18, 2025 10:35AM KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-
Oct 18, 2025 10:30AM KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer W
Oct 18, 2025 06:00AM KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Ba
Oct 16, 2025 06:45AM Merck KEYNOTE-B96 trial shows survival benefit in ovarian cancer patients
Oct 16, 2025 06:45AM Merck Announces Phase 3 KEYNOTE-B96 Trial Met Secondary Endpoint of Overall Survival (OS) in All Comers Population of Patients With Platinum-Resistant Recurrent Ovarian Cancer
Oct 15, 2025 08:01AM MilliporeSigma to acquire JSR Life Sciences chromatography business
Oct 15, 2025 08:00AM MilliporeSigma to Acquire Chromatography Business of JSR Life Sciences, Expanding Protein A Capabilities and Downstream Portfolio
Oct 15, 2025 06:45AM Merck presents new HIV drug trial data on weight and lipid effects
Oct 15, 2025 06:45AM Merck Announces New Data from Phase 3 Trials Evaluating the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) in Adults with Virologically Suppressed HIV-1 Infecti
Oct 9, 2025 07:00AM Merck to Present New Data from HIV Treatment and Prevention Pipeline at European AIDS Conference 2025
Oct 9, 2025 06:45AM Merck presents cancer research data at ESMO 2025 congress
Oct 9, 2025 06:45AM Merck Advances Oncology Innovation, Highlighting Progress in New Tumor Types and Earlier Stages of Disease at ESMO 2025
Oct 7, 2025 06:45AM Merck completes $10 billion acquisition of Verona Pharma
Oct 7, 2025 06:45AM Merck Completes Acquisition of Verona Pharma
Oct 6, 2025 06:45AM Merck starts phase 2b trials for tulisokibart in three new conditions
Oct 6, 2025 06:45AM Merck Expands Tulisokibart Clinical Development Program With Initiation of Phase 2b Trials in Three Additional Immune-Mediated Inflammatory Diseases
Oct 1, 2025 06:45AM Merck to Hold Third-Quarter 2025 Sales and Earnings Conference Call Oct. 30
Sep 30, 2025 03:39AM Merck's WINREVAIR reduces clinical worsening events by 76% in early PAH patients
Sep 30, 2025 03:39AM WINREVAIR™ (sotatercept-csrk) Reduced the Risk of Clinical Worsening Events by 76% Compared to Placebo in Patients Recently Diagnosed With PAH on Background Therapy in Phase 3 HYPERION Trial
Sep 19, 2025 05:32PM FDA approves Merck's subcutaneous KEYTRUDA QLEX across 38 cancer indications
Sep 19, 2025 05:31PM FDA Approves Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA® (pembrolizumab)
Sep 19, 2025 06:56AM Merck receives positive EU opinion for RSV prevention drug ENFLONSIA
Sep 19, 2025 06:50AM Merck Receives Positive EU CHMP Opinion for ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) in Infants During Their First RSV Season
Sep 19, 2025 06:45AM Merck receives positive EU opinions for KEYTRUDA subcutaneous form and head cancer use
Sep 19, 2025 06:45AM Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Head and Neck Cancer
Sep 15, 2025 07:01AM Daiichi Sankyo and Merck receive FDA breakthrough designation for ovarian cancer drug
Sep 15, 2025 07:00AM Raludotatug Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancers Previously Treate
Sep 11, 2025 06:45AM Merck reports positive trial results for pneumonia vaccine in children
Sep 11, 2025 06:45AM CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Children and Adolescents at Increased Risk of Pneumococcal Disease
Sep 7, 2025 10:45AM Daiichi Sankyo and Merck report phase 2 trial results for lung cancer drug
Sep 7, 2025 10:45AM Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
Sep 2, 2025 06:45AM Merck's oral cholesterol drug meets key goals in phase 3 trial
Sep 2, 2025 06:45AM Merck’s Investigational Oral PCSK9 Inhibitor Enlicitide Decanoate Met All Primary and Key Secondary Endpoints in Adults with Hypercholesterolemia in Pivotal CORALreef Lipids Study
Sep 2, 2025 06:30AM Merck to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
View More Recent Stories View Older Stories